Israel’s role as a leader in the research and development of medical cannabis products was given another boost last week when Israeli-Canadian cannabis startup SciCann Therapeutics entered into a strategic partnership with Global Cannabis Applications Corp. (GCAC) of Vancouver, Canada.
SciCann will develop the drugs while GCAC will qualify trial candidates and analyze the resulting data using a variety of clinical research tools, including artificial intelligence and blockchain.
Last month, IBM proposed using blockchain cryptocurrency to track cannabis sales, which today are conducted nearly entirely in cash because most medical cannabis dispensaries in the United States and Europe cannot secure bank accounts or accept credit cards.
SciCann develops cannabis-based therapeutic products for oncology, pain management, neurogenerative diseases and inflammatory disorders. The company is headed by Zohar Koren, who cofounded a previous medical cannabis company, Cannabics Pharmaceuticals, in 2012.
“By combining our scientific research and clinical data with GCAC technologies, we can deliver superior data